This article was originally published in Start Up
Syntropharma Ltd. aims to take known drugs that can be improved via transdermal delivery, or gain product life-extension through reformulation in the novel delivery mechanism. The company is focusing on two candidates: a transdermal selegiline patch for depression (aimed at the European market) and a patch formulation of naltrexone, an opioid receptor antagonist for battling dependence on alcohol and opiates.
You may also be interested in...
AllTranz Inc. has technology suitable for making pro-drugs out of opioids and cannabinoids, and it thinks these can be developed as treatments for a wide range of indications, from neuropathic pain to addiction, pancreatitis, and more. The company is leading, however, with a gel formulation that combines cannabidiol and penetration enhancers to treat the pain of osteoarthritis as well as strains and sprains.
Start-ups continue to seize opportunities for delivering new and existing drugs transdermally. They are also poised to capitalize on next-generation technologies for delivering macromolecules through the skin. In this issue, we profile AllTranz, Ocelus, Quinnova Pharmaceuticals and Syntropharma.
Ocelus Ltd. hopes to extend transdermal delivery to macromolecules. Its early-stage technology combines a microchip reservoir with microneedles that could painlessly inject precise yet tiny amounts of a drug into the skin at hundreds of sites per square centimeter. This could make administration simpler, and by reducing the pain associated with injectable drugs, improve patient compliance.